Old drug, new target: can a fibrosis pill boost chemo against lung cancer?
NCT ID NCT03177291
Summary
This early-stage trial tested adding an approved lung fibrosis drug, pirfenidone, to standard first-line chemotherapy for people with advanced non-small cell lung cancer. The main goals were to find a safe combined dose and get early signs of whether the combination could help shrink tumors. The study involved 48 adults with advanced lung cancer who had not yet received chemotherapy for their metastatic disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.